Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | MT-CO2 | P00403 | 2/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28961100 | 1.00 | CA1 (0.35) | CA1CA2CA4KMT2ACYP3A4 | |
| SCHEMBL10932545 | 0.85 | CA1 (0.35) | CA1CA2CA4KMT2AMT-CO2 | |
| SCHEMBL3292560 | 0.83 | — | — | |
| SCHEMBL4374227 | 0.79 | MT-CO2 (0.46) | CA1CA2CA4KMT2AMT-CO2 | |
| SCHEMBL3277309 | 0.79 | CA1 (0.43) | CA1CA2CA4KMT2AMT-CO2 | |
| SCHEMBL6535460 | 0.79 | MT-CO2 (0.46) | CA1CA2CA4KMT2AMT-CO2 | |
| SCHEMBL10719777 | 0.79 | MT-CO2 (0.46) | CA1CA2CA4KMT2AMT-CO2 | |
| SCHEMBL535670 | 0.76 | CA1 (0.55) | CA1CA2CA4KMT2AMT-CO2 | |
| SCHEMBL1101567 | 0.74 | — | — | |
| SCHEMBL15829440 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7241551-B2 | Positive-working resist composition | FUJIFILM CORPORATION (JP) | 2007-07-10 | — | — | US | disclosed |
| US-7241551-B2 | Positive-working resist composition | FUJIFILM CORPORATION (JP) | 2007-07-10 | — | — | US | disclosed |
| EP-0713702-B1 | ANXIOLYTIC AGENT | TAIHO PHARMACEUTICAL CO LTD (JP) | 2004-09-29 | — | — | EP | disclosed |
| US-6500819-B2 | HAS AN EXCELLENT ANXIOLYTIC EFFECT | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 2002-12-31 | — | — | US | disclosed |
| EP-0790237-B1 | BICYCLOLACTAM COMPOUNDS, USE OF THE SAME AND INTERMEDIATE IN THE PRODUCTION OF THE SAME | TAIHO PHARMACEUTICAL CO LTD (JP) | 2002-09-18 | — | — | EP | disclosed |
| US-20020099048-A1 | Bicycloloactam compounds, use thereof and intermediates for preparing thereof | TAIHO PHARMACEUTICAL COMPANY LIMITED | 2002-07-25 | — | — | US | disclosed |
| US-6355668-B1 | ANXIOLYTIC AGENTS; SIDE EFFECT REDUCTION | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2002-03-12 | — | — | US | disclosed |
| US-6303623-B1 | TREATING ANXIETY IN A PATIENT IN NEED OF SUCH TREATMENT, COMPRISING ADMINISTERING BICYCLOLACTAM COMPOUND | TAIHO PHARMACEUTICAL CO LTD (JP) | 2001-10-16 | — | — | US | disclosed |
| US-6159987-A | Bicyclolactam compounds, use thereof and intermediates for preparing thereof | TAIHO PHARMACEUTICALS, CO. (JP) | 2000-12-12 | — | — | US | disclosed |
| US-6004975-A | ANXIOLYTIC AGENTS WITH SIDE EFFECT REDUCTION | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1999-12-21 | — | — | US | disclosed |
| EP-0790237-A1 | BICYCLOLACTAM COMPOUNDS, USE OF THE SAME AND INTERMEDIATE IN THE PRODUCTION OF THE SAME | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 1997-08-20 | — | — | EP | disclosed |
| EP-0713702-A1 | ANXIOLYTIC AGENT | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1996-05-29 | — | — | EP | disclosed |
| EP-0230557-A2 | 2,6-Dioxabicyclo[3.3.0]octane derivatives, their preparation and use as medicament | Heinrich Mack Nachf. (DE) | 1987-08-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099048-A1 | Bicycloloactam compounds, use thereof and intermediates for preparing thereof | CYP11B1, GABRA6, CYP11B2 | CA1 460/4885CA2 1934/4885CA4 2584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.